ADIPOQ and obesity disorder: The indication that LH3 regulates the posttranslational lysine modification of adiponectin makes it a potential candidate for the development of future therapeutic treatments for various metabolic and cardiovascular abnormalities associated with obesity and insulin resistance, which are linked to the dysregulation of adiponectin secretion.